DSIP

If you’ve heard about DSIP from a sleep podcast or biohacker forum and want to know whether the evidence backs the marketing, here’s the honest version.

DSIP is a 9-amino-acid peptide first isolated from rabbit brain in 1977 by Swiss researchers studying sleep induction in cats. It was named for its ability to promote delta-wave (slow-wave) sleep — the deep, restorative phase of sleep that becomes harder to enter as you age. Despite the descriptive name, DSIP’s mechanism in humans is poorly understood almost 50 years after discovery. It does not bind any single well-characterized receptor; instead, it appears to influence multiple systems including cortisol regulation, neurotransmitter balance, and sleep architecture, but the specifics remain unclear.

DSIP’s evidence base in humans is unusually thin for a compound that’s been studied this long. Most published research is from the 1970s and 1980s, with sample sizes under 20 subjects and methodologies that wouldn’t meet modern standards. Modern controlled trials are essentially absent. Practitioners and patients report effects on sleep quality, but those reports do not have the foundation of contemporary clinical research behind them.

There is no FDA-approved or clinically validated DSIP protocol. The dosing approaches below reflect what’s reported in practitioner literature and community use — not controlled trial data. They should be treated as starting points for a conversation with your provider, not as established standards.

Practitioner-reported approaches:

• Route: Subcutaneous injection (most common) or intranasal
• Typical reported dose: 100–500 mcg per administration
• Timing: 30–60 minutes before sleep
• Frequency: Often intermittent (every other night, or in 2–4 week courses) rather than nightly continuous use
• Effect timing: Some users report changes in sleep quality from the first dose; others report no perceived effect